# TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

> **NCT07502872** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Brown University** · enrollment: 30 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma
- High-grade B-cell Lymphoma
- Lymphoma
- Lymphoma, B-Cell

## Interventions

- **DRUG:** Tafasitamab
- **DRUG:** Polatuzumab vedotin
- **DRUG:** Glofitamab
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT07502872
- **Lead sponsor:** Brown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2029-12-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07502872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07502872, "TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07502872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*